Skip to content

Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

A First-In-Human Pilot Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03948360
Enrollment
12
Registered
2019-05-13
Start date
2017-09-07
Completion date
2019-12-31
Last updated
2019-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn Wound

Keywords

acute burn, thermal injury, wound, phototherapy, wound healing, antimicrobial

Brief summary

The primary purpose of this first-in-human, early feasibility study is to assess safety and feasibility of the Low-Irradiance Monochromatic Biostimulation (LIMB) System as a phototherapeutic intervention for the management of acute burn wounds. The prototype LIMB device will be evaluated for the occurrence of adverse events (treatment-related or otherwise) of the LIMB System, a portable, wearable, light-emitting system developed by Rogers Sciences, Inc. (RSI). The device will be administered in the small feasibility pilot to confirm design, usability and operating specifications that will inform procedures and endpoints of a subsequent large, multicenter clinical trial.

Interventions

DEVICELow-Irradiance Monochromatic Biostimulation (LIMB) Device

The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.

OTHERStandard of Care

Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.

Sponsors

Rogers Sciences Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

The study model is sequential. Arm I will consist of the first 3 participants, with each participant receiving LIMB phototherapy over standard of care (SOC). The subsequent participants will comprise Arm II, with each participant to receive only LIMB phototherapy without standard of care. Dose modifications of the phototherapy can be made in Arm II, and will be determined based on any treatment-related adverse events observed in Arm I. Up to 12 participants in total will be enrolled.

Eligibility

Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No

Inclusion criteria

* Patients receiving care at Shriners Hospitals for Children-Boston for a skin tissue injury. * Patients who have at least one wound with exposed area sufficient, in the Investigator's opinion, to receive LIMB therapy. * Willing and able to adhere to daily LIMB therapy protocol.

Exclusion criteria

* Patients deemed not medically stable by the treating Investigator. * Patients with clinical signs and symptoms of systemic infection at baseline. * Patients with burn wounds limited to their head and genitalia. * Patients who, in the opinion of the Investigator, will not require daily dressing changes. * Patients receiving photosensitizing agents that result in cutaneous phototoxicity prior to enrollment. Patients who have received one or more of the following photosensitizers cannot be enrolled into the study: photofrin, amiodarone, chloropromazine, fluoroquinolone antibiotics, thiazide diuretics, quinine, demethylchlortetracycline, psoralens, nalidixic acid, tetracycline, naproxen. * Patients currently enrolled or participating in another investigational device, drug or biological trial within 30 days of the Screening Visit. * Patients currently receiving any bandages or devices containing silver compounds. * Patients on a ventilator, who have fluid resuscitation or are in any terminal condition.

Design outcomes

Primary

MeasureTime frameDescription
Occurrence of Adverse Events from LIMB Phototherapy as Assessed by CTCAE v4.0up to 7 daysTo evaluate the occurrence of adverse events (treatment-related or otherwise) from LIMB phototherapy from the time of device application up to 7 days. Reporting consistent with CTCAE v4.0. Duration of LIMB phototherapy can be shortened per discretion of treating Investigator.

Secondary

MeasureTime frameDescription
Change in Bioburden assessed through Wound Cultureup to 7 daysTo evaluate the effect of LIMB phototherapy on microbial bioburden. Wound culture specimens are collected at each daily dressing change to measure the change in microbial bioburden when compared to baseline.

Other

MeasureTime frameDescription
Change in Pain as Assessed by Checklist Pain Behavior Scaleup to 7 daysTo evaluate the change in participant's pain score during LIMB phototherapy treatment. Pain assessments taken daily at dressing change.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026